Article

Strides Said to Consider Sale of Injectable-Drugs Unit

Strides Arcolab Ltd. (STR)

, a supplier of cancer-fighting drugs to Pfizer Inc., is considering selling its injectable-medicines unit, three people with knowledge of the matter said.

market value

The unit, called Agila Specialties, may be valued at more than Bangalore-based Strides’s current of about $800 million, two people said, declining to be identified as the information is private. Agila’s relative success in winning approvals for new products and the scarcity of facilities able to manufacture injectable medicines make it an attractive target for drugmakers, they said.

Read the full story: http://tinyurl.com/9c5zogt

Source: Bloomberg

Related Videos
Shawn Griffin, MD, sitting for a video interview
5 experts are featured in this series
5 experts are featured in this series
Christine Funke, MD
John Michael O'Brien, PharmD, MPH
Kathi Henson, MBA, sitting for a video interview
Mike Fazio, Navista, Cardinal Health
1 expert in this video
1 expert in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo